P G Cusumano1, D Generali2, E Ciruelos3, L Manso3, I Ghanem3, E Lifrange4, G Jerusalem4, J Klaase5, F de Snoo6, L Stork-Sloots6, L Dekker-Vroling6, M Lutke Holzik7. 1. CHU Sart Tilman, Liège, Belgium. Electronic address: pino@cusumano.be. 2. Istituti Ospitalieri di Cremona, Cremona, Italy. 3. Hospital Universitario 12 de Octubre, Madrid, Spain. 4. CHU Sart Tilman, Liège, Belgium. 5. Medisch Spectrum Twente, Enschede, The Netherlands. 6. Agendia NV, Amsterdam, The Netherlands. 7. Medisch Spectrum Twente, Enschede, The Netherlands; Saxenburgh Groep, Hardenberg, The Netherlands.
Abstract
AIM: To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort. METHODS: Breast cancer patients were prospectively enrolled and MammaPrint was assessed. Patients' clinical data without and then with MammaPrint results were sent to the different multidisciplinary teams and treatment advice was provided for each patient. RESULTS: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was changed in 37% of patients by the Dutch, 24% by the Belgian, 28% by the Italian and 35% by the Spanish teams. MammaPrint increased the inter-institutional agreement in treatment advice (chemotherapy or no chemotherapy) from 51% to 75%. CONCLUSION: The results of this study indicate that MammaPrint impacts adjuvant chemotherapy recommendation. MammaPrint can decrease inter-institutional and inter-country variability in adjuvant treatment advice for breast cancer patients.
AIM: To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort. METHODS:Breast cancerpatients were prospectively enrolled and MammaPrint was assessed. Patients' clinical data without and then with MammaPrint results were sent to the different multidisciplinary teams and treatment advice was provided for each patient. RESULTS: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancerpatients was changed in 37% of patients by the Dutch, 24% by the Belgian, 28% by the Italian and 35% by the Spanish teams. MammaPrint increased the inter-institutional agreement in treatment advice (chemotherapy or no chemotherapy) from 51% to 75%. CONCLUSION: The results of this study indicate that MammaPrint impacts adjuvant chemotherapy recommendation. MammaPrint can decrease inter-institutional and inter-country variability in adjuvant treatment advice for breast cancerpatients.
Authors: Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: S Pérez Ramírez; M Del Monte-Millán; S López-Tarruella; N Martínez Jáñez; I Márquez-Rodas; F Lobo Samper; Y Izarzugaza Perón; C Rubio Terres; D Rubio Rodríguez; J Á García-Sáenz; F Moreno Antón; P Zamora Auñón; M Arroyo Yustos; M Á Lara Álvarez; E M Ciruelos Gil; L Manso Sánchez; M J Echarri González; J A Guerra Martínez; C Jara Sánchez; C Bueno Muiño; S García Adrián; J R Carrión Galindo; V Valentín Maganto; M Martín Journal: Clin Transl Oncol Date: 2019-07-12 Impact factor: 3.405
Authors: Julia E C van Steenhoven; Bianca M den Dekker; Anne Kuijer; Paul J van Diest; Peter Nieboer; Johanna M Zuetenhorst; Alex L Th Imholz; Sabine Siesling; Thijs van Dalen Journal: Breast Cancer Res Treat Date: 2020-05-19 Impact factor: 4.872
Authors: A Kuijer; A C M van Bommel; C A Drukker; M van der Heiden-van der Loo; C H Smorenburg; P J Westenend; S C Linn; E J Th Rutgers; S G Elias; Th van Dalen Journal: Genet Med Date: 2015-11-19 Impact factor: 8.822